The FDA flagged potential safety signals for colitis with Ibrance, Kisqali and Verzenio, and heart inflammation with melanoma drugs. No causal link is confirmed.
|Articles|December 22, 2021
Part 1: My Experiences as a Bladder Cancer Caregiver with Beáta Baker
Beáta Baker cared for her husband, Steven, as he battled his unexpected diagnosis and subsequent bladder removal surgery (radical cystectomy).
Advertisement
Episode 16, Part 1 of the
In an engaging and personal conversation, Beáta describes her journey and growth as a caregiver. Rick and she discuss:
- What was it like to be Steven’s caregiver at different points in his journey, like diagnosis, treatment, recovery and planning?
- How did you and Steven decide upon right doctor, the right hospital, and the right treatment?
- What roles did you play during treatment planning?
- What were some of the challenging and rewarding parts of being a caregiver?
Advertisement
Related to this article
A biomarker test changed one mother’s diagnosis from suspected glioblastoma to ependymoma, but the report written in October did not reach her until December.
Anktiva is now approved for BCG-unresponsive papillary-only bladder cancer. Here’s what the bladder-sparing option involves, from timeline to risks.
The approval adds patients with high-grade papillary-only tumors, based on trial data showing a 62% complete response rate in patients with carcinoma in situ.
The 2026 cancer report found U.S. cancer death rates continued to fall from 2019 to 2023, largely due to lung cancer progress, while diagnoses rose slightly among women.
Patients with a newly identified tumor state had shorter survival following chemotherapy and immunotherapy, potentially helping doctors identify those at greater risk of poor outcomes.
Longer follow-up of the phase 2 LUNAR trial showed a 62% lower risk of progression, additional hormone therapy or death with 177Lu-PNT2002 plus radiation.
Medicare's cap on out-of-pocket drug costs has made cancer pills more affordable, but premiums, formularies and prior authorization rules still vary widely. Here's a checklist.
Advertisement
Advertisement
Trending on CURE
1
FDA Expands Anktiva Approval in BCG-Unresponsive Bladder Cancer
2
Radioligand Plus Radiation Delays Prostate Cancer Progression to 17.6 Months
3
Anktiva for Papillary Bladder Cancer: What Patients Should Know
4
Why Biomarker Testing Can Change a Brain Tumor Diagnosis
5